Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07022977 | A Study of MET233 in Individuals With Obesity or Overweight | PHASE1 | COMPLETED | 144 | — | — | Nov 6, 2024 | Apr 21, 2026 | May 26, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| (Part A) MET233 | EXPERIMENTAL | Participants will receive a single dose of MET233 at up to 5 dose levels |
| (Part A) Placebo | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo |
| (Part B) MET233 | EXPERIMENTAL | Participants will receive five weekly doses of MET233 at up to 4 dose levels |
| (Part B) Placebo | PLACEBO_COMPARATOR | Participants will receive five weekly doses of placebo |
| (Part C) MET233 | EXPERIMENTAL | Participants will receive twelve weekly doses of MET233 at up to 4 dose levels, followed by a 13th potential monthly dose |
| (Part C) Placebo | PLACEBO_COMPARATOR | Participants will receive twelve weekly doses of placebo, followed by a 13th potential monthly dose |
| (Part D) MET233 | EXPERIMENTAL | Participants will receive twelve weekly doses of MET233, followed by three monthly doses. |
| (Part D) Placebo | PLACEBO_COMPARATOR | Participants will receive twelve weekly doses of placebo, followed by three monthly doses. |
| Name | Type | Description |
|---|---|---|
| MET233 | BIOLOGICAL | For subcutaneous administration |
| Placebo | BIOLOGICAL | Sterile 0.9% (w/v) saline for subcutaneous administration |
Inclusion Criteria: * Adult (≥18 to ≤70 years) male and female participants with obesity or overweight (BMI 27.0 kg/m2 to 38.0 kg/m2, inclusive) but otherwise healthy. Exclusion Criteria: * Female who is lactating or who is pregnant according to the pregnancy test at the Screening visit or prior ...